Vortioxetine
LuAA21004_401
Phase 1 small_molecule completed
Quick answer
Vortioxetine for Severe Hepatic Impairment is a Phase 1 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Severe Hepatic Impairment
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- completed